Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.

被引：0
|
作者：
Gutierrez, Martin
Subbiah, Vivek
Nemunaitis, John J.
Mettu, Niharika B.
Papadopoulos, Kyriakos P.
Barve, Minal A.
Feliz, Luis
Lihou, Christine Francis
Tian, Chenwei
Ji, Tao
Silverman, Ian M.
Chugh, Rashmi
Saleh, Mansoor N.
机构：
[1] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[3] Univ Toledo, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[6] Mary Crowley Canc Res Ctr, Dallas, TX USA
[7] Incyte Biosci Int Sarl, Geneva, DE, Switzerland
[8] Incyte Corp, Wilmington, DE USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Univ Alabama Birmingham, Birmingham, AL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3606
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael S.
    Wolf, Ido
    Fakih, Marwan
    de Vos-Geelen, Judith
    Lee, Valerie
    Vogel, Arndt
    Wu, Xi Lawrence
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [22] An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa
    Giamarellos-Bourboulis, E. J.
    Pelekanou, E.
    Antonopoulou, A.
    Petropoulou, H.
    Baziaka, F.
    Karagianni, V.
    Stavrianeas, N.
    Giamarellou, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (03) : 567 - 572
  • [23] Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.
    Liu, Tianshu
    Yang, Mudan
    Li, Jin
    Pan, Yueyin
    Yuan, Ying
    Yi, Shanyong
    Wang, Junsheng
    Cheng, Ying
    Feng, Jifeng
    Gao, Shegan
    Wang, Xicheng
    Qu, Song
    Zhang, Xizhi
    Lu, Jin
    Xiu, Peng
    Wang, Shuni
    Yang, Xinfeng
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
    Gumbleton, Matthew
    Allan, Stephanie
    Conway, Hannah
    Boucher, Kenneth
    Marvin, James
    Hawks, Josiah
    Burnett, William
    Van Brocklin, Matthew
    Whisenant, Jonathan
    Gilcrease, Glynn
    Gupta, Sumati
    BMC RESEARCH NOTES, 2023, 16 (01)
  • [25] A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
    Matthew Gumbleton
    Stephanie Allan
    Hannah Conway
    Kenneth Boucher
    James Marvin
    Josiah Hawks
    William Burnett
    Matthew Van Brocklin
    Jonathan Whisenant
    Glynn Gilcrease
    Sumati Gupta
    BMC Research Notes, 16
  • [26] Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
    Zucali, Paolo Andrea
    Lin, Chia-Chi
    Carthon, Bradley C.
    Bauer, Todd M.
    Tucci, Marcello
    Italiano, Antoine
    Iacovelli, Roberto
    Su, Wu-Chou
    Massard, Christophe
    Saleh, Mansoor
    Daniele, Gennaro
    Greystoke, Alastair
    Gutierrez, Martin
    Pant, Shubham
    Shen, Ying-Chun
    Perrino, Matteo
    Meng, Robin
    Abbadessa, Giovanni
    Lee, Helen
    Dong, Yingwen
    Chiron, Marielle
    Wang, Rui
    Loumagne, Laure
    Lepine, Lucie
    de Bono, Johann
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [27] A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)
    Infante, Jeffrey
    Ahlers, Christoph M.
    Hodi, F. Stephen
    Postel-Vinay, Sopie
    Schellens, Jan H. M.
    Heymach, John V.
    Autio, Karen
    Barnette, Mary
    Struemper, Herbert
    Watmuff, Maura
    Paul, Elaine M.
    Kaufman, David R.
    Weber, Jeffrey S.
    Hoos, Axel
    CANCER RESEARCH, 2016, 76
  • [28] Efficacy and safety of vitamin K with sorafenib combination treatment against hepatocellular carcinoma: Open-label, randomized phase II study.
    Haruna, Yoshimichi
    Inoue, Atsuo
    Kawamoto, Seiichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.
    Zhang, Bo
    Wang, Xi
    Zhu, Lingjun
    Li, Qun
    Liu, Yun
    Qi, Ling
    Shu, Yongqian
    Huang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
    Koshkin, V. S.
    Barthelemy, P.
    Gravis, G.
    Goodman, O.
    Duran, I.
    Girones Sarrio, R.
    Hwang, C.
    Garcia-Donas, J.
    Morales Barrera, R.
    Zanetta, S.
    Chisamore, M.
    Liu, M.
    Gil, M.
    Tomlinson, G.
    Elsayed, H.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1136 - S1137
12345